论文部分内容阅读
Objective: Patients with metastatic colorectal cancer are now recommended to profile for RAS and BRAF mutations before receiving cetuximab or panitumumab.However, lots of patients with both RAS and BRAF wild-type tumors determined by non-NGS testing might still notrespond due to the presence of additional gene mutation such as PIK3CA or PTEN.